Publications by authors named "Mikel Berdud"

Claim this Profile
U
Understanding biopharmaceutical investment decision-making: how does Congressional Budget Office's model compare to investor insights?
Matthias P Hofer, Priscila Radu, Mikel Berdud, Amanda Cole, Graham Cookson

Health Aff Sch· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach.
Mikel Berdud, Jimena Ferraro, Adrian Towse

Front Health Serv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom.
Mikel Berdud, Niklas Wallin-Bernhardsson, Bernarda Zamora, Peter Lindgren, Adrian Towse

Value Health· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing a reasonable price for an orphan drug.
Mikel Berdud, Michael Drummond, Adrian Towse

Cost Eff Resour Alloc· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incentives and intrinsic motivation in healthcare.
Mikel Berdud, Juan M Cabasés, Jorge Nieto

Gac Sanit· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What do pharmaceuticals really cost in the long run?
Darius Lakdawalla, Joanna P MacEwan, Robert Dubois, Kimberly Westrich, Mikel Berdud

Am J Manag Care· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilars: How Can Payers Get Long-Term Savings?
Jorge Mestre-Ferrandiz, Adrian Towse, Mikel Berdud

Pharmacoeconomics· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis